Frequently Asked Questions

Yes, absolutely. The active ingredient — semaglutide — is chemically identical whether it's compounded by a pharmacy or manufactured by Novo Nordisk (Ozempic/Wegovy). The difference is in the delivery method and manufacturing process, not the medication's efficacy. In Dr. Moleon's clinical practice, she has prescribed both brand-name and compounded semaglutide to hundreds of patients, and the weight loss results are equivalent. Compounding offers the same therapeutic effect at a fraction of the cost.

Most patients notice reduced appetite within the first 1–2 weeks and see initial weight loss (2–5 pounds) within the first month. However, GLP-1 medications work gradually — we start at a low dose and increase slowly to minimize side effects and optimize results. Peak weight loss typically occurs around 16–20 weeks as we reach therapeutic doses. On average, patients lose 1–2 pounds per week, with total weight loss of 15–20% of their body weight over 6–12 months.

Based on clinical trial data for the referenced FDA-approved medication. Individual results vary. These results do not establish the safety or effectiveness of compounded medications.

Yes. Clinical trials demonstrate semaglutide's safety for at least 2+ years of continuous use, and many patients have been on it longer with excellent tolerance. Obesity is a chronic condition, much like high blood pressure or diabetes, and long-term medication is often necessary for sustained results. We monitor patients regularly with lab work and check-ins to ensure ongoing safety.

No. This is a common concern because the FDA requires a "black box" warning based on animal studies showing thyroid tumors in rodents at extremely high doses. However, there is no evidence that semaglutide causes thyroid cancer in humans. Millions of people have used GLP-1 medications since 2017, and human clinical trials have not shown increased thyroid cancer risk. As a precaution, we don't prescribe semaglutide to patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

The most common side effects are nausea (20–30% of patients), diarrhea or constipation (10–15%), fatigue, and headaches. These are typically mild and resolve within 4–8 weeks as your body adjusts to the medication. We manage side effects by starting at a low dose and increasing gradually (slow titration), recommending smaller protein-rich meals, staying hydrated, and avoiding greasy or spicy foods. If nausea persists, we may slow down dose increases or prescribe anti-nausea medication.

We start patients at 0.25 mg weekly for the first 4 weeks to minimize side effects. Then we increase to 0.5 mg for 4 weeks, then 1.0 mg, 1.5 mg, 2.0 mg, and finally 2.5 mg if needed for optimal weight loss. This gradual titration allows your body to adjust comfortably. Some patients achieve excellent results at 1.0–2.0 mg and don't need the maximum dose. Dosing is personalized based on individual response, tolerance, and weight loss goals.

No, you can inject semaglutide at any time of day, with or without food. The medication stays active in your system for about a week, so the specific timing doesn't significantly impact efficacy. We recommend choosing a consistent day and time each week (e.g., Sunday morning) to make it part of your routine.

If you realize you missed your dose within 5 days, take it as soon as you remember and resume your regular weekly schedule. If it's been more than 5 days, skip the missed dose and take your next dose on your regular day. Never double up on doses to "catch up." Missing one dose won't ruin your progress, but try to maintain consistency for best results.

Semaglutide is injected subcutaneously (under the skin) in areas with more fatty tissue — primarily the abdomen, thighs, or upper arms. The abdomen (around the belly button area, avoiding the 2-inch radius directly around your navel) tends to have the most consistent absorption. We recommend rotating injection sites each week to prevent irritation or lumps under the skin. The injection itself is quick and relatively painless using the thin needles provided.

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist, meaning it activates two hormone receptors instead of one. Clinical trials show slightly higher average weight loss with tirzepatide (20–25% of body weight) compared to semaglutide (15–20%). However, individual response varies significantly. Some patients respond better to semaglutide, while others prefer tirzepatide. Cost is also a factor — compounded semaglutide is often more affordable. We'll recommend the best option based on your health history and goals.

Based on clinical trial data for the referenced FDA-approved medication. Individual results vary. These results do not establish the safety or effectiveness of compounded medications.

Yes, absolutely. Many patients have switched from brand-name Ozempic or Wegovy to compounded semaglutide to save money — the active ingredient is identical, so the transition is seamless. We simply match your current dose and continue your treatment without interruption. Your results and side effect profile should remain the same, but you'll save significantly on cost.

GLP-1 medications like semaglutide and tirzepatide represent a breakthrough in obesity treatment. They work differently than older weight loss drugs (like phentermine or orlistat) by targeting the hormones that regulate appetite, blood sugar, and metabolism. Many patients who had minimal success with previous medications achieve significant weight loss with GLP-1 therapy. Clinical trial data shows 80–85% of patients lose ≥5% of their body weight on these medications.

Based on clinical trial data for the referenced FDA-approved medication. Individual results vary. These results do not establish the safety or effectiveness of compounded medications.

Yes! Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (orforglipron — the newest oral GLP-1 from Eli Lilly) are FDA-approved specifically for weight loss in people without diabetes. The criteria are: BMI ≥30, or BMI ≥27 with at least one weight-related condition (high blood pressure, high cholesterol, sleep apnea, etc.). Many patients use GLP-1 medications solely for weight management and metabolic health, not diabetes treatment.

While semaglutide will help you lose weight even without major lifestyle changes (by reducing appetite and cravings), combining the medication with healthy eating and regular exercise significantly enhances results and long-term success. We recommend focusing on protein-rich meals (to preserve muscle mass), resistance training 2–3x per week, and daily movement.

Many patients regain some weight after stopping semaglutide because appetite regulation returns to baseline. To maintain your weight loss, you'll need to continue healthy eating habits, regular exercise, and the metabolic awareness you developed during treatment. Many patients choose to stay on a maintenance dose of semaglutide indefinitely — the same way someone with high blood pressure stays on their medication long-term.

We recommend at least 0.8–1.0 grams of protein per pound of ideal body weight daily to preserve muscle mass during weight loss. For most patients, this means 80–120 grams of protein per day spread across meals. Since semaglutide reduces appetite, it's important to prioritize protein-rich foods first at each meal before filling up on carbohydrates or fats.

Moderate alcohol consumption is generally safe on semaglutide, but many patients report reduced alcohol tolerance and less interest in drinking. Alcohol may increase nausea and gastrointestinal side effects, especially when you're first starting treatment. We recommend limiting alcohol to 1–2 drinks per week, staying well-hydrated, and avoiding drinking on an empty stomach.

Foundayo (orforglipron) is the newest FDA-approved GLP-1 from Eli Lilly · approved April 1, 2026 · and the first oral GLP-1 that's a true alternative to injections. It's a once-daily tablet you swallow, no needles required. In clinical trials (ATTAIN-1), patients lost an average of about 12% of their body weight at the highest dose, which is slightly less than Wegovy injection (~15%) and meaningfully less than Zepbound (~20–22%). For patients who are needle-averse, travel often, or simply prefer a pill, that trade-off is often worth it. Dr. Moleon will help you weigh whether the convenience of a daily pill outweighs the slightly higher weight loss you might see with injections.

Based on clinical trial data for the referenced FDA-approved medication. Individual results vary. These results do not establish the safety or effectiveness of compounded medications.

No fasting required with Foundayo. Both are oral GLP-1s, but Foundayo is much more flexible. Wegovy Pill requires you to take it on an empty stomach with a small sip of water and wait 30 minutes before eating, drinking anything else, or taking other medications. Foundayo has no food, water, or timing restrictions · take it any time of day, with or without food. That makes daily adherence much easier for most people, especially anyone with a busy morning routine or who takes other medications.

Yes · this is exactly who Foundayo was designed for. If needle aversion has kept you from trying GLP-1 therapy, or if you've struggled with weekly self-injections, Foundayo gives you a real option: a once-daily tablet, no injection at all. Many patients have put off GLP-1 treatment for years specifically because of the needles. Foundayo removes that barrier completely while still delivering meaningful weight loss (~12% on average at the top dose). It's also a great fit for frequent travelers · no needles to pack, no refrigeration concerns, no TSA conversations.

Based on clinical trial data for the referenced FDA-approved medication. Individual results vary. These results do not establish the safety or effectiveness of compounded medications.

Compounding pharmacies prepare custom formulations for individual patients using the same FDA-approved active ingredient (semaglutide). They don't carry the massive R&D, marketing, and patent costs of brand-name manufacturers like Wegovy, Zepbound, or Foundayo (orforglipron, the newest oral GLP-1 from Eli Lilly), which allows them to offer the medication at $229/month instead of $1,000–1,500/month. The quality is excellent — compounding pharmacies are regulated by state boards of pharmacy and follow strict sterility and quality standards.

Most insurance plans do not cover compounded medications. However, at $229/month, compounded semaglutide is often cheaper than insurance copays for brand-name options like Wegovy, Zepbound, or Foundayo (orforglipron, the newest oral GLP-1 from Eli Lilly). You can use HSA/FSA funds to pay for compounded semaglutide since it's a prescription medication for a diagnosed medical condition. Many patients find the self-pay compounded route more convenient and affordable than dealing with insurance prior authorization.

At Body Good, we handle all prior authorization paperwork for you. Typical turnaround is 48–72 hours, though some plans take up to 5–7 business days. We submit all necessary documentation (BMI, weight-related conditions, medical necessity) to maximize approval chances. If your insurance denies coverage, you have two options: appeal the decision (which we can help with) or switch to our affordable self-pay compounded program at $229/month.

We understand that cost is a barrier for many patients. Here are some options: (1) Check if your insurance covers brand-name Wegovy, Zepbound, or Foundayo — we'll handle prior authorization, (2) Use HSA/FSA funds if available, (3) Some patients start with every-other-week dosing to reduce costs (though this may slow results). At $229/month, compounded semaglutide is already one of the most affordable GLP-1 options available — compare that to $1,500/month for brand-name without insurance.

Foundayo (orforglipron) is sold directly through LillyDirect® Pharmacy under Eli Lilly's Self Pay Journey Program. Pricing is tiered by dose: $149/month for the lower doses (0.8mg, 2.5mg, 5.5mg, 9mg) and $349/month for the higher doses (14.5mg, 17.2mg). The $349/month higher-dose pricing requires refilling within 45 days of your previous order · we send reminders so you don't lose the discount. With eligible commercial insurance plus the Foundayo savings card, your out-of-pocket may be as low as $25/month. Medicare Part D coverage at around $50/month is expected July 2026. Body Good charges a separate one-time $49 for your physician consultation and e-prescription · the medication itself is paid directly to LillyDirect when they ship it.

Yes! Semaglutide is often very beneficial for women with PCOS (polycystic ovary syndrome). Many patients see improvements in insulin resistance, menstrual regularity, testosterone levels, and fertility in addition to weight loss. However, if you're planning to conceive, you should stop semaglutide at least 2 months before trying to get pregnant, as there's insufficient data on pregnancy safety. Use reliable contraception while on treatment.

Absolutely! Semaglutide is FDA-approved and highly effective for weight loss in both men and women. Clinical trials included both sexes, and men often achieve excellent results with GLP-1 therapy. Men may even lose weight slightly faster than women due to higher baseline metabolic rates and muscle mass. The dosing, side effects, and benefits are the same regardless of gender.

Semaglutide is FDA-approved for weight loss in adults (18+) and adolescents (12+) with obesity. For patients under 18, we require parental consent and often recommend a more conservative approach focusing on lifestyle modification first. For adults of any age, semaglutide is safe and effective — age alone is not a barrier to GLP-1 therapy.

Yes! In fact, semaglutide often helps improve both conditions. Many patients see reduced blood pressure and better blood sugar control with weight loss. We may need to adjust your blood pressure or diabetes medications as you lose weight to prevent hypoglycemia or low blood pressure. Regular monitoring is important, but these conditions don't disqualify you from GLP-1 therapy — they're often the very reasons we prescribe it.